Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
144.85
+0.51 (0.35%)
Oct 30, 2026, 4:00 PM EST - Market closed
Protagonist Therapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Reiterates $155 → $160 | Buy | Reiterates | $155 → $160 | +10.46% | Oct 21, 2026 |
| Citi | Citi | Buy Maintains $182 | Buy | Maintains | $182 | +25.65% | Oct 15, 2026 |
| Barclays | Barclays | Buy Maintains $180 | Buy | Maintains | $180 | +24.27% | Oct 13, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $150 → $190 | Buy | Initiates | $150 → $190 | +31.17% | Oct 12, 2026 |
| UBS | UBS | Buy Initiates $184 | Buy | Initiates | $184 | +27.03% | Oct 12, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $186 | Buy | Maintains | $186 | +28.41% | Sep 1, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $149 | Buy | Reiterates | $149 | +2.87% | Sep 1, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 1, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.